Business Context and Reporting Period
This Form 8-K is a current report filed by Indaptus Therapeutics, Inc. (INDP) on June 1, 2026, covering events occurring on June 1 and June 5, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The filing discloses significant changes to the Company's leadership structure:
- Board Resignations: Effective June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions and committee roles on the Board of Directors.
- Executive Resignation: Effective June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as Chief Operating Officer.
- Consulting Transition: Mr. Linscott will continue to serve the Company as a consultant under an agreement dated June 1, 2026.
Management Commentary and Risks
Management explicitly stated that the resignations of Mr. Lazar, Mr. Ben-Tzvi, and Mr. Linscott were not the result of any disagreement with the Company regarding its operations, policies, or practices. The Board expressed gratitude for the services of the departing directors and indicated an intention to continue working with Mr. Linscott in his new strategic advisory capacity. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the effective dates of the resignations (June 1 and June 5, 2026) against the Company's official press releases.
- Confirm the terms of the new consulting agreement with Mr. Walt A. Linscott, including compensation and scope of work.
- Check for subsequent filings regarding the appointment of new directors or a replacement Chief Operating Officer.
- Review the Company's most recent 10-K or 10-Q for baseline financial health, as this 8-K contains no financial metrics.